Impact of nerve surgery on opioid and medication use in patients with chronic nerve injuries by Felder, John M & Ducic, Ivica
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
9-1-2021 
Impact of nerve surgery on opioid and medication use in patients 
with chronic nerve injuries 
John M Felder 
Ivica Ducic 







































Disclosure: The authors have no financial interest to declare 
in relation to the content of this article.
From the *Division of Plastic and Reconstructive Surgery, 
Department of Surgery, Washington University in St. Louis, St. 
Louis, Mo.; and †Washington Nerve Institute, McLean, Va.
Received for publication May 2, 2021; accepted June 30, 2021.
Presented at the American Society for Peripheral Nerve National 
Meeting (online, during COVID-19 pandemic), January 15, 2021.
This study was approved by an independent IRB.
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, 
Inc. on behalf of The American Society of Plastic Surgeons. This 
is an open-access article distributed under the terms of the Creative 
Commons Attribution-Non Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible to download and share the 
work provided it is properly cited. The work cannot be changed in 




Chronic nerve injuries may be considered those inju-
ries that manifest in patients seeking outpatient care. 
These may result from an untreated acute injury to a 
nerve, or may result from a progressive chronic process, 
such as untreated compression neuropathy. Untreated 
injuries to peripheral nerves may act as chronic pain gen-
erators, which can have a debilitating effect on physical 
functioning and quality of life. Pain management with 
medications is therefore frequently employed, including 
with opioid medications.1 For various reasons, chronic 
pharmacologic pain management with opioids and other 
medications is often used even for conditions where surgi-
cal interventions are available to correct the underlying 
anatomical cause of the chronic pain.
Recently, the national opioid crisis has highlighted 
the potential individual and societal harms associated 
with chronic opioid use.2–5 Therefore, interventions with 
the potential to reduce the chronic use of opioids have 
become a topical matter. Patients with neuropathic pain 
(NP) are more likely than patients with non-neuropathic 
chronic pain to be taking opioids and multiple pain medi-
cations, but they report less pain relief from their medica-
tions.6 Interestingly, despite an increased focus on opioid 
alternatives, consideration of nerve surgery as an option 
to address NP is largely absent from medical algorithms 
and consensus recommendations.7–11
Given that nerve surgery is a rational, traditional, and 
literature-supported approach to correcting injuries of 
peripheral nerves, whether due to trauma or compres-
sion neuropathy,12–18 this study was undertaken to evaluate 
specifically whether nerve surgery was associated with a 
postoperative reduction in chronic medication and opioid 
use among patients with chronic pain due to nerve inju-
ries. We hypothesized that nerve surgery, across a broad 
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Introduction: Limited information is available regarding the ability of nerve sur-
gery to affect medication use patterns in patients with chronic pain or neuropathy 
due to nerve injury. 
Methods: A retrospective survey was distributed to all operative patients (N = 767) 
from a single nerve surgeon’s practice between 2014 and 2020. Data collected 
included demographics, specifics of the injury and symptoms, medication and opi-
oid use before surgery, and medication/opioid use following surgery.
Results: Out of the 767 patients, 209 (27.2%) completed the survey. Average age was 
48.8 (SD = 19.1) years; 68.9% female and 31.1% male. More than 50% of the patients 
took at least three medications. More than 50% of the patients after surgery did not 
need medication or had significant reduction; 54.1% of the patients took opioid 
medication daily, and  97.3% of patients reported that narcotic medications did not 
resolve their problem. Patients rated the effectiveness (Likert scale 0–10) of opioid 
medications in general at an average 3.25 ± 2.03. Of patients who took opioids regu-
larly, 61.6% reported a negative effect of these medications on daily or professional 
activities. After surgery, more than 50% of the patients did not need opioids or had 
a significant reduction in opioid usage.
Conclusions: Untreated nerve injuries lead to ongoing chronic pain, explaining 
why medications are mostly ineffective in eliminating symptoms. In this study, nerve 
surgery targeting the anatomical source of symptoms effectively reduced both opi-
oid and nonopioid medication use. (Plast Reconstr Surg Glob Open 2021;9:e3789; doi: 
10.1097/GOX.0000000000003789; Published online 7 September 2021.)
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spectrum of conditions, would reduce patients’ depen-
dence on chronic medication and opioid use.
METHODS
An IRB-approved retrospective survey from a single 
nerve surgeon’s ambulatory referral-based practice was 
distributed to all patients (N = 767) who underwent sur-
gery for NP or dysfunction between 2014 and 2019. The 
minimum follow-up period was 1 year. Data collected 
included demographics, etiology of the injury, concur-
rent clinical conditions, specifics of nerve injury/disorder 
type, duration and severity of the symptoms at presenta-
tion, medications and opioids used before surgery to treat 
the nerve problem (eg, not medications for other chronic 
medical conditions), effects of opioid use on quality of 
life, medication/opioid use following surgery, severity of 
symptoms following surgery, and complications of surgery.
RESULTS
Characteristics of the Patient Group
Out of the 767 patients, 209 (27.2%) completed the 
survey. Average age was 48.8 (SD = 19.1) years; 68.9% were 
women and 31.1% men. Notable comorbidities included 
anxiety (31.1%), depression (28.2%), and thyroid disor-
ders (11.0%) (Table 1).
Anatomical areas affected included the head and neck 
in 119 patients (56.9%), lower extremity in 62 (29.7%), 
upper extremity in 19 (9.1%), trunk/groin in six (2.9%), 
breast in two (1%), and multiple areas in one (0.5%) 
(Table 1); 16.3% had spontaneous onset, 53.1% had suf-
fered a physical trauma, and 30.6% were precipitated by 
previous surgery (Fig. 1A and B).
Presenting symptoms included pain 192 (91.9%), 
numbness 82 (39.2%), tingling/burning 129 (61.7%), 
muscle weakness 45 (21.5%), difficulty using arm or leg 
46 (22%), headaches/migraines 111 (53.1%), and others 
less than 10% (Table 1).
Affected quality of life variables included sleep pattern 
in 78.5% of the patients, social life in 87.5%, extremity 
function in 44.0%, personal/social life in 87.6%, profes-
sional activities in 71.8%, and mood/spirits in 83.7%.
The duration of symptoms before presentation is dis-
tributed as follows: less than 3 months (3.8%), 3–6 months 
(8.1%), 6–12 months (20.1%), 1–2 years (25.8%), 3–5 
years (21.1%), 5–10 years (10.0%), and more than10 years 
(11.0%). Sixty-eight percent (95% CI = [61.2%, 74.2%]) 
of patients had symptoms for more than 1 year before 
surgery.
The percentage of patients who reported the severity 
of symptoms at presentation as being profound was 86.1% 
(95% CI = [80.7%, 90.5%]). At the time of presentation, the 
mean ± SD Likert scale (0–10) severity score was 8.1 ± 2.0 
(median = 9). After the nerve surgery, the mean ± SD Likert 
scale (0–10) severity score was 3.2 ± 3.0 (median = 2). The 
change (reduction mean ± SD = 4.9 ± 3.6; median = 5) 
was statistically significant (P < 0.001 by Wilcoxon signed 
rank test).
Surgery types included neurolysis in 108 (51.67%) 
patients, neuroma excision with implantation to muscle in 
seven (3.33%), neuroma excision and nerve reconstruc-
tion in 90 (42.86%), and excision of nerve tumor in four 
(1.90%) (Table 1).
Medication Use before and after Surgery
The total number of all medications used daily before 
nerve surgery was: zero in 10.5% of patients, one to two in 
31.1%, three to four in 28.2%, five to six in 16.3%, seven 
to eight in 7.2%, nine to 10 in 2.4%, 11–12 in 1.4%, and 
more than 12 in 2.9%. Significantly, more than 50% of the 
patients took at least three medications daily (P = 0.018). 
All patients reported that medications did not resolve their 
problem, with an average effectiveness (Likert scale 0–10) 
of mean ± SD = 2.5 ± 1.9 (median = 2) (Fig. 2).
After surgery, patients reported their use of all medica-
tions as follows: (1) for those who did not need to take 
medications before the surgery, 0% had to take medica-
tion after the surgery and (2) for those who took medica-
tions before the surgery, medication use was completely 
eliminated in 34.2% of patients, significantly reduced in 
25.1%, moderately reduced in 13.4%, somewhat reduced 
in 7.5%, not affected in 17.1%, and made worse in 2.7%. 
Significantly, more than 50% of the patients after surgery 
did not need medication or had significant reduction 
(P = 0.0008) (Fig. 3).
Total daily opioid medication use before surgery was 
zero in 45.9% of patients, one to three in 39.2%, four to 
Table 1. Patient Demographics
Age





Survey respondents 209 27.2
Sex   
 Male 65 31.1
 Female 144 68.9
Comorbidities   
No comorbidities 77 36.8
Anxiety 65 31.1
Depression 59 28.2
Peripheral vascular disease 31 14.8
Thyroid disorders 23 11
Autoimmune diseases 18 8.6
Diabetes 13 6.2
Cancer 10 4.8
Presenting symptoms   
 Pain 192 91.9
 Numbness 82 39.2
 Tingling/burning 129 61.7
 Muscle weakness 45 21.5
 Difficulty using arm or leg 46 22






 Neurolysis 455 (59.32%) 108 (51.67%)
 Neuroma excision +  
 implantation to muscle
42 (5.48%) 7 (3.33%)
 Excision and reconstruction 256 (33.38%) 90 (42.86%)






 Head and neck 484 (63.10%) 119 (56.9%)
 Breast/chest 4 (0.52%) 2 (0.96%)
 Upper extremity 71 (9.26%) 20 (9.57%)
 Lower extremity 163 (21.25%) 62 (29.67%)
 Trunk/groin 45 (5.87%) 6 (2.87%)
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six in 12.0%, seven to nine in 1.9%, and 10–13 in 0.96%. 
The percentage of patients who took opioid medication 
daily was 54.1% (95% CI = [47.1%, 61.0%]), and 97.3% 
(95% CI = [92.3%, 99.4%]) of patients reported that opi-
oid medications did not resolve their problem. Patients 
rated the effectiveness (Likert scale 0–10) of opioid medi-
cations in general at an average (mean ± SD) of 3.25 ± 
2.03 (median = 3). Of patients who took opioids regularly, 
61.6% (95% CI = [51.9%, 70.6%]) reported a negative 
effect of these medications on daily or professional activi-
ties (Fig. 4).
After surgery, patients reported their use of opioids  
as follows: (1) for those who did not need to take opioids 
before the surgery, 1% took opioids after the surgery; (2) 
for those who took opioids before the surgery, opioid 
use was completely eliminated in 56.3% of patients, sig-
nificantly reduced in 12.5%, moderately reduced in 8.9%, 
somewhat reduced in 6.3%, not affected in 14.3%, and 
made worse in 1.8%. Significantly, more than 50% of the 
patients after surgery no longer required opioid medica-
tions or had significant reduction in use (P = 2.9 × 10−13) 
(Fig. 5).
Complication rate was 8.3% and all complications 
were minor (delayed wound healing, dehiscence due to 
noncompliance, infection requiring oral antibiotics), with 
no complications requiring hospitalization or return to 
the operating room
DISCUSSION
Opioid medications have increasingly been recog-
nized to have detrimental effects both on the individual 
patient and society.2,3,19 Although chronic opioid use is a 
frequently observed clinical phenomenon in patients with 
chronic pain due to nerve injuries,1,7–9,20 surprisingly few 
studies have attempted to quantify the degree of medica-
tion and opioid use in such patients,21 or commented on 
whether nerve surgery has an effect on reducing opioid 
consumption in these patients.15 Generally speaking, the 
commonly employed nonsurgical modalities for treatment 
of chronic pain (including medications, but also interven-
tional procedures such as neuromodulation or ablation) 
are mechanistically unable to reverse the underlying ana-
tomical cause of pain and instead are directed at control-
ling or “masking” symptoms. It is therefore conceptually 
Fig. 1. Spectrum of posttraumatic nerve injuries included. a, nerve injuries following trauma. B, nerve injuries following surgery.
Fig. 2. Medications taken to address nerve-related problem before surgery.
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straightforward to suppose that the unresolved underlying 
mechanisms of pain generation will require ongoing use 
of medications, contributing to the chronic use of opioids 
that has recently been labeled as a crisis in our society.
Nerve surgery, in contradistinction, is directed at revers-
ing the causative anatomical lesion responsible for produc-
ing chronic pain. Generally speaking, nerve surgery has 
been demonstrated to be effective in treating chronic NP 
due to a wide variety of underlying traumatic or compres-
sive etiologies.12–15,22 Over the past two decades of clinical 
practice in nerve surgery, we have informally observed the 
frequently present burden of chronic medication and opi-
oid use among preoperative patients, and the phenome-
non of reduction in medication/opioid use postoperatively 
Fig. 3. effect of nerve surgery on total nerve-related medication use in patients with chronic nerve pain. *By exact binomial test.
Fig. 4. total daily opioid use and effectiveness before surgery in patients with chronic nerve pain.
 Felder and Ducic • Impact of Nerve Surgery on Opioid Use
5
in some cases. We therefore conducted this study within our 
own nerve surgery practice to verify and quantify to what 
degree nerve surgery may have an effect on the reduction 
of total medications and/or opioids in patients with chronic 
pain, functional nerve deficits, or compression neuropathy
This study was designed as a retrospective survey 
to achieve the longest possible follow-up after surgery. 
Although outcomes such as pain scores were included 
in the study results, this study was not intended to be a 
validated outcomes study regarding the effectiveness of 
nerve surgery for relief of symptoms. Rather, traditional 
outcome measures were only included to give some idea 
of the correlation between medication reduction and 
patient-reported outcomes for effectiveness of surgery.
The primary findings of this study support the hypoth-
esis that nerve surgery is effective in significantly reducing 
dependence on chronic medications, including opioids 
across a broad range of peripheral nerve pathologies 
where surgery is indicated. Specifically, medication use 
was completely eliminated in 34.2% of patients, and more 
than 50% of patients after surgery either did not need 
medication or had at least a meaningful reduction in the 
number of medications needed, a result that reached sta-
tistical significance (Fig.  3). With regards to opioids in 
particular, opioid use was completely eliminated in 56.3% 
of patients, and more than 50% of patients after surgery 
either no longer required opioid medications or had a 
meaningful reduction in use (Fig. 5). It is interesting to 
note that 68% of the patients had symptoms for more than 
1 year before surgery, which suggests that even delayed 
surgical intervention may have an effect on opioid reduc-
tion; a question that has been persistent in the literature.23
Although it may seem obvious, it is also relevant that 
nearly 100% of patients self-reported that medications “did 
not resolve their pain problem” (Figs. 2 and 4). Being a refer-
ral-based surgical practice, our group may have self-selected 
for a predominance of patients in whom medications were 
not effective. However, guidelines from the European 
Federation of Neurological Societies regarding pharmaco-
therapy for NP suggest that only 30%–40% of patients with 
chronic NP achieved pain relief of greater than 50% with 
pharmacotherapy.10,11 In other published cross-sectional 
surveys of patients with NP, three-fourths had moderate or 
severe pain despite taking oral medications for their pain.24–29
Mechanistically, in the case of an anatomically identi-
fiable lesion of a peripheral nerve, medications are not 
able to reverse the underlying process leading to pain or 
dysfunction. However, there is certainly evidence in the lit-
erature, including from randomized controlled trials, that 
a variety of drugs including opioids are capable of improv-
ing symptoms of NP, including the level of pain itself.24 
Several of the first-line medications for NP, including tri-
cyclic antidepressants, duloxetine, gabapentin, pregaba-
lin, and opioids have all produced statistically significant 
improvements in sleep compared to placebo. Overall 
mood, anxiety, and depression have also been shown to 
improve in randomized controlled trial subjects treated 
with those same drugs. However, there is evidence to sug-
gest that such associations are not at all consistent among 
patients with NP and may also be dependent on underly-
ing intrinsic patient factors, making pharmacologic treat-
ment of NP an often frustrating, trial-and-error process.24 
Among patients in the United Kingdom followed for the 
first year after being diagnosed with NP, only 30%–50% 
had stable treatment regimens.30 Furthermore, among 
Swedish patients with peripheral NP, two of three had 
discontinued at least one treatment because of poor pain 
relief, adverse effects, or both.31
Fig. 5. effect of nerve surgery on daily opioid use in patients with chronic nerve pain. *By exact binomial test.
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Our patients subjectively rated the average “effective-
ness” of opioid treatment for NP as 3.25 on a Likert scale 
of 0–10. Furthermore, 61.6% of our patients reported 
that opioids had a negative effect on daily or professional 
activities (Fig. 4). Taken together, these results suggest a 
high degree of ineffectiveness as well as a morbidity to 
treatment with opioid medications in patients referred for 
surgery, with the potential morbidity being both personal 
and socioeconomic.19,32
The reported low effectiveness and notable morbid-
ity of opioids in our respondents may be due to selection 
bias, given that all of our patients were referred for surgery 
likely because other treatments were ineffective. However, 
both findings also support the concept that medications 
are unable to reverse etiology and thereby, when used as 
a sole form of treatment, create a condition of chronic 
medication use, whereas surgery is effective in altering the 
underlying etiology and therefore may reduce the need 
for chronic treatment. Finally, one may speculate that 
promoting the paradigm of chronic pharmacologic treat-
ment of conditions with an underlying surgically treatable 
cause may cause a doubly negative effect on the patient by 
effectively converting a potentially curable condition into 
a chronic condition that both burdens the patient with 
medication side effects while also putting the onus of find-
ing effective surgical treatment on them.
Limitations of the study include a relatively low 
response rate, which may have to do with attrition of 
respondents over a long study period. There were dif-
ferences in survey response rates among surgery types; 
however, the percentage of respondents by surgery type 
generally approximated the percentage of the patient 
population who had undergone that surgery type.
The broad spectrum of conditions treated may skew 
results, as some nerve injury conditions may have been non-
painful and predominantly related to loss of function. These 
limitations preclude us from drawing definitive conclusions 
regarding the magnitude of the effect of nerve surgery on 
decreasing opioid consumption. On the other hand, these 
data clearly indicate a positive effect of nerve surgery involve-
ment, in general, in reducing medication and opioid use 
in chronic nerve injury patients. Despite some study limita-
tions, our findings do serve to call awareness to the issues of 
polypharmacy and opioid use in patients with chronic pain 
related to nerve injuries, and suggest that surgical treatment 
is a potential means of reducing reliance on medications in 
this population. More rigorous prospective studies are indi-
cated to confirm these preliminary conclusions.
CONCLUSIONS
Chronic use of opioids is increasingly considered to 
be detrimental to patients and society. In this study, we 
demonstrated quantifiably that nerve surgery can reduce 
chronic dependence on opioids and other medications 
among patients with NP due to various types of nerve 
injuries, and of varying duration. Nerve surgery should 
be considered alongside pharmacologic treatments within 
medical treatment algorithms as an option for chronic NP 
due to nerve injury. Future prospective studies are indi-
cated to confirm these findings.
Ivica Ducic, MD, PhD
Washington Nerve Institute
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